Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Exagen Inc.

Filed: Jun 9, 2026CIK: 0001274737
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Exagen Inc. held its 2026 annual stockholder meeting on June 9, 2026, electing two Class I directors for three-year terms. Tina S. Nova, Ph.D. and Scott Kahn, Ph.D. were elected with strong stockholder support, reflecting confidence in the company's strategic direction.

Key Takeaways

Tina S. Nova, Ph.D. elected as Class I director with 8,094,349 votes for and 220,954 withheld, demonstrating overwhelming stockholder support

Scott Kahn, Ph.D. elected as Class I director with 6,295,837 votes for and 2,019,466 withheld, indicating solid but comparatively lower support

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 9, 2026
Item5.02
CategoryExecutive Change
CIK0001274737
Accession #0001274737
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings